EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Take Solutions Limited (TAKE) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Take Solutions Limited ₹4.17, price ₹12.65, upside -67.0%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · IN · ISIN INE142I01023

TS Thin data Sep 27, 2026

Take Solutions Limited

TAKE · NSE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value ₹4.17 · Strongly overvalued (−67.0%)
✓Quality 61/100
!Weak Growth (revenue 5y −41.2 %/yr)
✓Highly profitable · 20.0% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (4/12)
!Narrow moat 39/100
!Evidence only low, so the estimate is less certain
Watch Take Solutions Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹70.25 ₹6.69 Fair Value ₹4.17 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range ₹6.69 – ₹70.25 · fair‑value band ₹3.56 – ₹5.98 · the ₹12.65 price screens above the ₹4.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.

Follow Take Solutions in your weekly email

Every Wednesday you see whether Take Solutions is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise.

Show more

TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient centricity insight in life science sector; and payer solutions, including access to billing insight through cloud adoption. In addition, the company offers payer-provider digital solution, which includes personalized medicine, wellness, and patient engagement; and medical device solution, such as technological transformation with chip level programming, DICOM devices, wearables, PROM, nano devices, and miOTs. TAKE Solutions Limited was incorporated in 2000 and is based in Chennai, India.

Stock analysis

Take Solutions Limited (TAKE) currently trades at ₹12.65, while our model-based Fair Value estimate is ₹4.17, 67.0% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹12.61 per share, and 1 of the 10 models we run sit above the ₹12.65 price.

Bear case: the Asset-Based group reads lowest at ₹1.42, and 9 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: ₹3.56 (bear) to ₹5.98 (bull), the price of ₹12.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Take Solutions Limited reported revenue of ₹542M in FY2026 versus ₹6.5B in FY2022, a compound −46.3%/yr. Reported net income was ₹108M in FY2026.

Key figures

Market cap ₹3.3B (≈ $34.7M) · P/E ratio 43.6 · P/S ratio 8.73 · EPS (TTM) ₹0.2900 · Dividend yield 0.0% · Net margin 20.0% · Return on equity 16.5% · Return on assets (EBIT) −6.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −67%, TAKE screens richer than that median.

Fair Value models

Bear ₹3.56 Fair Value ₹4.17 Bull ₹5.98
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.1470 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings ₹5.48 ₹7.25 ₹10.72 77
Residual Income ₹3.87 ₹4.48 ₹6.66 75
Gordon GGM ₹0.0200 ₹0.0300 ₹0.0300 69
All 10 models by family
DCF Models
Owner Earnings ₹5.48 ₹7.25 ₹10.72 77
Earnings-Based
Graham-Dodd ₹5.05 ₹8.11 ₹9.78 67
Dividend Discount
Gordon GGM ₹0.0200 ₹0.0300 ₹0.0300 69
DDM Multi-Stage ₹0.0200 ₹0.0300 ₹0.0400 67
Multiples
P/E Multiple ₹12.24 ₹16.32 ₹20.40 63
P/S Multiple ₹9.46 ₹12.61 ₹15.77 58
P/B Multiple ₹7.16 ₹9.54 ₹11.93 55
Asset-Based
NCAV (Graham) ₹1.06 ₹1.42 ₹2.12 54
Economic Profit
Residual Income ₹3.87 ₹4.48 ₹6.66 75
Growth Earnings
Growth-Adj P/E ₹8.63 ₹12.33 ₹16.03 67

Open the full fair value analysis →

Notify me when TAKE reaches fair value

Put TAKE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 61/100

Of which business quality 59 · Market factors (momentum, volatility) 29

Profitability 76
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 94
Disciplined investing over empire-building
Low Volatility 58
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 22/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−41.2%
Start year 2021 (pandemic). Over 10 years: −25.5% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−19.4% (2021) → −3.5% (2026)

TAKE screens overvalued: fair value 67% below the price. Compare with Veeva Systems Inc →

Compare Take Solutions Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 118 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 61 · Above median
Fair Value upside −67.0% · Bottom 25%
Profitability
Return on equity (TTM) 16.5% · Top 25%
Return on assets −3.3% · Below median
Net margin (TTM) 20.0% · Top 25%
Operating margin (TTM) −1.5% · Below median
Growth and dividend
Revenue growth −82.9% · Bottom 25%
Dividend yield (TTM) 0.0% · Bottom 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (TTM) 43.6× · Pricier than median
P/B 10.77× · Priciest 25%
P/S (TTM) 6.16× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)66 · sector 12
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 44

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $278.57 $306.43 +10%
Pro Medicus Limited PME A$161.00 A$84.62 −47%
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54%
Hinge Health, Inc HNGE $95.57 $51.25 −46%
HealthEquity, Inc HQY $88.44 $97.28 +10%
Waystar Holding WAY $24.70 $27.17 +10%
Doximity, Inc DOCS $26.35 $31.41 +19%
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81%
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6%
Privia Health Group PRVA $19.62 $5.02 −74%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Take Solutions Limited · Fair Value
₹4.17 −67%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Take Solutions Limited Fair Value". https://www.fairvalue-calculator.com/stock/TAKE

Frequently asked questions

Is Take Solutions Limited (TAKE) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹4.17 versus a price of ₹12.65, about −67% upside (overvalued).
What is the fair value of TAKE?
Our model-based fair value for Take Solutions Limited is ₹4.17 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹12.65.
What is the quality score of TAKE?
Take Solutions Limited has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Take Solutions Limited (TAKE)?
Our model-based price target is the fair value of ₹4.17 (as of Sep 27, 2026) from 10 valuation models. Cautious scenario ₹3.56, optimistic scenario ₹5.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Take Solutions Limited stock forecast for 2026?
Our models put fair value at ₹4.17, about −67% upside versus a price of ₹12.65 (overvalued). Cautious scenario ₹3.56, optimistic scenario ₹5.98. The calculation is refreshed regularly with new filings.
What is the revenue of Take Solutions Limited (TAKE)?
Take Solutions Limited reported trailing-twelve-month revenue of about ₹542M (latest available figure, as of Sep 27, 2026).
Does Take Solutions Limited pay a dividend?
Take Solutions Limited currently shows a dividend yield of about 0.01% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Take Solutions Limited (TAKE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Take Solutions Limited it is ₹4.17 per share (as of Sep 27, 2026), against a price of ₹12.65. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Take Solutions Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, TAKE trades above its calculated fair value: price ₹12.65, fair value ₹4.17, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TAKE?
No. The price is what the market pays today (₹12.65); the fair value is what the company's own numbers justify (₹4.17). For Take Solutions Limited the two are ₹8.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Take Solutions Limited worth?
The market values Take Solutions Limited at about ₹3.3B (market capitalisation, as of Sep 27, 2026). Per share that is ₹12.65; our models calculate a fair value of ₹4.17 per share.
What do the bullish and bearish scenarios say about TAKE?
Our models span a range for Take Solutions Limited: cautious scenario ₹3.56, base ₹4.17, optimistic ₹5.98 per share (as of Sep 27, 2026, price ₹12.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TAKE?
Take Solutions Limited trades at a price-to-earnings ratio of 43.6 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹4.17 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2017 to 2026), reported earnings: 12.4. Other multiples: P/B 10.8, P/S 6.2.
How solid is the balance sheet of Take Solutions Limited (TAKE)?
Balance-sheet figures for Take Solutions Limited (as of Sep 27, 2026): return on equity 16.5%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is TAKE from its 52-week high?
Take Solutions Limited trades at ₹12.65, about 75% below its 52-week high of ₹50.14 and 5% above the low of ₹12.06 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹4.17 is for.
Which stocks are comparable to Take Solutions Limited?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Take Solutions Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹12.65, calculated fair value ₹4.17 (−67%), Quality Score 61/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TAKE calculated?
We run Take Solutions Limited through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹4.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Take Solutions Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Take Solutions Limited (TAKE)?
The closing price on Oct 1, 2026 was ₹12.65. Our model-based fair value is ₹4.17, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Take Solutions Limited right now?
The price sits above even our optimistic bull case (₹5.98). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Take Solutions Limited

How large is the market capitalisation of Take Solutions Limited (TAKE)?
The market capitalisation of Take Solutions Limited is ₹3.3B (≈ $34.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Take Solutions Limited (TAKE)?
The price-to-sales ratio of Take Solutions Limited is 8.73 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Take Solutions Limited (TAKE)?
Earnings per share at Take Solutions Limited are ₹0.2900 (price ÷ EPS = P/E 43.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Take Solutions Limited (TAKE)?
The dividend yield of Take Solutions Limited is 0.0% (payout 0.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Take Solutions Limited (TAKE)?
The net margin of Take Solutions Limited is 20.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Take Solutions Limited (TAKE)?
The return on equity (ROE) of Take Solutions Limited is 16.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Take Solutions Limited (TAKE)?
On an EBIT basis the return on assets of Take Solutions Limited is −6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Take Solutions Limited (TAKE)?
The operating margin of Take Solutions Limited is −1.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Take Solutions Limited (TAKE)?
Revenue at Take Solutions Limited is growing −82.9% versus a year earlier (3y avg −34.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Take Solutions Limited (TAKE)?
Earnings per share at Take Solutions Limited are growing −97.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Take Solutions Limited (TAKE) generate?
The free cash flow of Take Solutions Limited is −₹41.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Take Solutions Limited (TAKE) hold?
Take Solutions Limited holds more cash than debt, ₹2.8M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Take Solutions Limited in the live analysis

One click puts Take Solutions Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.